Tag Archives: mRCC

December, 2017

February, 2017

June, 2016

  • 13 June

    IDMC Recommends Continuation of Argos Therapeutics Late-Stage RCC Study

    DURHAM, N.C., June 13, 2016 (GLOBE NEWSWIRE) — Argos Therapeutics Inc. (Nasdaq:ARGS), an immuno-oncology company focused on the development and commercialization of truly individualized immunotherapies for the treatment of cancer based on the Arcelis® technology platform, today announced that the independent data monitoring committee (IDMC) for the Company’s pivotal Phase …